Our Mission

The V Foundation is a charitable organization dedicated to saving lives by helping to find a cure for cancer. The Foundation seeks to make a difference by generating broad-based support for cancer research and by creating an urgent awareness among all Americans of the importance of the war against cancer. The Foundation performs these dual roles through advocacy, education, fundraising, and philanthropy.
The V Foundation awards three types of grants. The **V Scholar Grant** provides funds directly to young scientists to establish their own independent laboratory. The **Translational Grant** facilitates the transition of projects from the laboratory to the clinic. The **Designated Grant** funds projects in communities or regions local to the fundraising area.

### 2012 V Scholars

**Hiu Wing Cheung, Ph.D.**  
Hollings Cancer Center  
Medical University of South Carolina  
Charleston, SC  
*Role of ID4 in ovarian cancer development and metastasis*

**Christina Curtis, Ph.D.**  
USC Norris Comprehensive Cancer Center  
University of Southern California  
Los Angeles, CA  
*Interrogating patient-specific tumor dynamics through single cell profiles and computational modeling*

**Todd Fehninger, M.D., Ph.D.**  
Siteman Cancer Center  
Washington University School of Medicine  
St. Louis, MO  
*Enhanced innate immunity to cancer utilizing human memory-like NK cells*

**Daniel A. Harki, Ph.D.**  
Masonic Cancer Center  
University of Minnesota  
Minneapolis, MN  
Funded by Delta Chi Fraternity  
*Beyond parthenolide: next generation molecules targeting AML cancer stem cells*

**Justin D. Lathia, Ph.D.**  
Cleveland Clinic Lerner College of Medicine  
Cleveland, OH  
Albert Wyrick V Scholar Award  
Funded by the Michael and Carole Marks Family  
*Holding on to stemness: targeting mechanisms that maintain glioblastoma stem cells*

**Qing Li, M.D., Ph.D.**  
University of Michigan Comprehensive Cancer Center  
University of Michigan  
Ann Arbor, MI  
*NRAS signaling in hematopoietic stem cells and leukemic stem cells*

**Unhee Lim, Ph.D.**  
University of Hawaii Cancer Center  
Honolulu, HI  
*Investigating global leukocyte DNA methylation for predicting colorectal cancer risk in a multiethnic population*

**Mohammad (Mo) Motamedi, Ph.D.**  
Massachusetts General Hospital Cancer Center  
Charlestown, MA  
*The role of sirtuins in epigenetics and genomic stability*

**Trudy G. Oliver, Ph.D.**  
Huntsman Cancer Institute  
University of Utah  
Salt Lake City, UT  
Funded by the Thomas Carroll Family  
In memory of Christopher T. Carroll  
*Understanding Myc’s role in small cell lung cancer*

**Asha Bhaskaran Pillai, M.D.**  
St. Jude Children’s Research Hospital  
Memphis, TN  
*Augmenting cytotoxicity of ex vivo expanded human iNKT cells for cancer immunotherapy*

**Jeffrey W. Tyner, Ph.D.**  
Knight Cancer Institute  
Oregon Health and Science University  
Portland, OR  
*Translation of novel mutations in CSF3R into validated therapeutic modalities*

**Christopher R. Vakoc, M.D., Ph.D.**  
Cold Spring Harbor Laboratory  
Cold Spring Harbory, NY  
*Therapeutic targeting of the polycomb complex PRC2 in acute myeloid leukemia*
Jeffrey Venstrom, M.D.
UCSF Helen Diller Family Comprehensive Cancer Center
University of California at San Francisco
San Francisco, CA
Funded by The V Foundation Wine Celebration Volunteer Grant
In honor of Derek and Cathy Reisinger
Mechanisms and strategies for recruiting natural killer cells to cure acute myeloid leukemia

Jessie Villanueva, Ph.D.
The Wistar Institute
Philadelphia, PA
Establishing molecular targets for NRAS driven melanomas: an unmet medical need

Sarah (Sadie) Wignall, Ph.D.
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL
Targeting centrosome-clustering mechanisms to selectively kill cancer cells

Monte M. Winslow, Ph.D.
Stanford Cancer Institute
Stanford University
Stanford, CA
Martin D. Abeoff, M.D. V Scholar Award*
Functional characterization of Nkx2-1 regulated genes that govern lung cancer metastasis

Xiaoyang Wu, Ph.D.
University of Chicago Comprehensive Cancer Institute
Chicago, IL
Spectraplakin and coordinated cytoskeletal dynamics in colorectal cancer

*The research project that receives the highest rating by the Scientific Advisory Board will annually be designated as the Martin D. Abeloff, M.D. V Scholar Award.

2012 TRANSLATIONAL GRANTS

Steven P. Balk, M.D., Ph.D.
Huihui Ye, MMSc.
Glenn Bubley, M.D.
Martin Sanda, M.D.
Beth Israel Deaconess Medical Center
Boston, MA
Molecular characterization of gleason 3 tumors that progress to gleason 4

Michele Carbone, M.D., Ph.D.
Haining Yang, Ph.D.
Ian Pagano, Ph.D.
University of Hawaii Cancer Center
Honolulu, HI
HMGB1: A biomarker for mineral fiber exposure and detection of malignant mesothelioma

Reuben S. Harris, Ph.D.
Douglas Yee, M.D.
Masonic Cancer Center
University of Minnesota
Minneapolis, MN
Funded by The V Foundation Wine Celebration Vintner Grant
In honor of Suzanne Pride-Bryan
Role of DNA deamination in breast cancer

Nora Heisterkamp, Ph.D.
Steven Mittelman, M.D., Ph.D.
Yong-mi Kim, M.D., Ph.D.
Children’s Hospital Los Angeles
Los Angeles, CA
Improving treatment outcome in leukemia by disruption of bone-marrow leukemia interactions relevant to minimal residual disease

Angela M. Hartley Brodie, Ph.D.
University of Maryland School of Medicine
Funded by Friends of V Baltimore Golf Classic
Targeting mechanisms of resistance to hormone therapy in breast cancer

Miaofen G. Hu, M.D., Ph.D.
Richard Van Eten, M.D., Ph.D.
Tufts Medical Center
Medford, MA
CDK6 as a novel therapeutic target in T-cell acute lymphoblastic leukemia

Mark C. Lanasa, M.D., Ph.D.
Sandeep Dave, M.D., M.S.
Duke Cancer Institute
Duke University Medical Center
Durham, NC
Genetic determinants of progression in chronic lymphocytic leukemia

Anthony E. Oro, M.D., Ph.D.
Jean Y. Tang, M.D., Ph.D.
Stanford Cancer Institute
Stanford University
Stanford, CA
Novel therapies for hedgehog-dependent cancers

W. Kimryn Rathmell, M.D., Ph.D.
Jason Lieb, Ph.D.
Ian Davis, M.D., Ph.D.
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, NC
Funded by the Jimmy V Celebrity Golf Classic
In memory of Girard Tillery
Reprogramming the histone methylation code of renal cell carcinoma

Martine F. Roussel, Ph.D.
Amar Gajjar, M.D.
St. Jude Children’s Research Hospital
Memphis, TN
Identification and pre-clinical testing of compounds to treat group 3 medulloblastoma
2012 DESIGNATED GRANTS

Kimberly Stegmaier, M.D.
James E. Bradner, M.D.
Lisa R. Diller, M.D.
Dana-Farber Cancer Institute
Boston, MA
Therapeutic targeting of N-Myc with BET bromodomain inhibition in neuroblastoma

Corrine Linardic, M.D., Ph.D.
Duke Cancer Institute
Duke University Medical Center
Durham, NC
Funded by Apple Gold Group
Understanding SFRP’s contribution to alveolar rhabdomyosarcoma tumorigenesis

All Children’s Hospital
Dick Vitale Pediatric Cancer Research Fellowship
St. Petersburg, FL
Funded by the Dick Vitale Gala

University of Texas MD Anderson Cancer Center
Pediatric Cancer
Funded by LG Electronics Home Court Advantage

Victoria F. Borges, M.D., MMSc
University of Colorado Cancer Center
Denver, CO
Funded by the Kay Yow Cancer Fund
Pilot study the prevention of postpartum pregnancy associated breast cancer

Nehal Parikh, M.D.
Connecticut Children’s Medical Center
Hartford, CT
Funded by ESPN, Inc.
Isolation and characterization of cancer stem cells in neuroblastoma tumor model

Ian Davis, M.D., Ph.D.
UNC Lineberger Comprehensive Cancer Center at UNC
Funded by the Jimmy V Celebrity Golf Classic
Targeting deregulated transcription in pediatric cancers

St. Helena Hospital Foundation
St. Helena, CA
Funded by The V Foundation Wine Celebration

James M. Ford, M.D.
Stanford Cancer Institute
Stanford University
Palo Alto, CA
Funded by the Gastric Cancer Foundation

University of Texas MD Anderson Cancer Center
Houston, TX
SPORE in Ovarian Cancer
Funded by the Kay Yow Cancer Fund

Peter Forsyth, M.D.
H. Lee Moffitt Cancer Center and Research Institute
University of South Florida
Tampa, FL
Funded by the Dick Vitale Gala
Developing myxoma virus as an experimental treatment for brain cancer stem cells in children and adults with malignant gliomas

Daniel S. Wechsler, M.D., Ph.D.
Duke Cancer Institute
Duke University Medical Center
Durham, NC
Funded by Apple Gold Group
Strike while the iron is not: targeting CALM-rearranged leukemias by iron deprivation

Susan Goodin, PharmD.
Cancer Institute of New Jersey
Robert Wood Johnson Medical School
University Medical Center
New Brunswick, NJ
Funded by Marketing Research Consultants
Prevention of prostate cancer progression by atorvastatin and celecoxib

Hai Yan, M.D., Ph.D.
Duke Cancer Institute
Duke University Medical Center
Durham, NC
Supplemental SPORE
Funded by The V Foundation Wine Celebration and Accelerate Brain Cancer Cure
Developing novel approaches to target gliomas

Ramaswamy Govindan, M.D.
Siteman Cancer Center
Washington University School of Medicine
St. Louis, MO
Funded by UNICO
In memory of Dorothy Jean Varsalona
Molecular assay to predict outcomes in resected NSCLC using nanostring technology

Steven Zeitels, M.D., FACS
Massachusetts General Hospital Cancer Center
Boston, MA
Funded by the Dick Vitale Gala
Voice preservation in the treatment of early glottic (laryngeal) cancer
The V Foundation Board of Directors is entrusted with and accountable for the strategic leadership and governance of the organization. The Board is comprised of prominent business leaders, award-winning athletes and coaches, distinguished physicians and world-renowned entertainers. Their governance is integral to the sustainability and long-term effectiveness of the Foundation in ways that are consistent with our core values and principles.
Robert Valvano  
Sports Commentator

Lesley Visser  
Sports Commentator  
CBS and HBO

Dick Vitale  
Sports Commentator  
ESPN, Inc. and ABC Sports

R.C. “Bucky” Waters  
Retired Vice Chancellor/Special Projects  
Duke University Medical Center  
Sports Commentator  
ESPN, Inc. & Madison Square Garden

Robert P. Wayman  
Retired Chief Financial Officer and Executive Vice President  
Hewlett-Packard Company

Dereck Whittenburg  
Sports Commentator  
ESPN, Inc.

David W. Williams  
Retired Senior Vice President  
Whirlpool Corporation

Norby Williamson  
Executive Vice President, Programming & Acquisitions  
ESPN, Inc.

Larry Woodard  
President and Chief Executive Officer  
Graham Stanley Advertising

Joseph O. Moore, M.D.  
Medical Director  
Duke Raleigh Cancer Center  
Professor, Hematology & Oncology  
Duke Cancer Institute

Robert C. Nakasone  
Retired Chief Executive Officer  
Toys “R” Us

Donna Orender  
Chief Executive Officer  
Orender Unlimited LLC

Lawrence F. Probst III  
Chairman of the Board  
Electronic Arts  
Chairman  
United States Olympic Committee

Harry E. Rhoads, Jr.  
Chief Executive Officer  
Washington Speakers Bureau  
Secretary  
The V Foundation for Cancer Research

Robin Roberts  
Co-Anchor  
ABC’s Good Morning America

John P. Saunders  
Sports Commentator  
ESPN, Inc. and ABC Sports

Constance E. Skidmore  
Former Board Member and Managing Partner  
PricewaterhouseCoopers LLC

John Skipper  
President  
ESPN, Inc.

Anthony F. Smith, Ph.D.  
Co-Founder and Managing Director  
Leadership Research Institute

Pamela Valvano Strasser  
Chairwoman  
The V Foundation for Cancer Research

Nicholas P. Valvano  
President Emeritus  
The V Foundation for Cancer Research
The Scientific Advisory Board is comprised of leading physicians and research scientists from prominent universities and cancer centers. The all-volunteer Scientific Advisory Board ensures that grant proposals meet the highest standards of scientific merit and that funding is properly allocated.

Robert C. Bast, Jr., M.D.
Vice President for Translational Research
MD Anderson Cancer Center
Houston, TX

William T. Beck, Ph.D.
Professor and Head
Department of Biopharmaceutical Sciences
University of Illinois at Chicago
Chicago, IL

Gerold Bepler, M.D., Ph.D.
President & Chief Executive Officer
Karmanos Cancer Institute
Detroit, MI

Lisa M. Coussens, Ph.D.
Hildegard Lamfrom Chair in Basic Science
Professor and Chair, Cell & Developmental Biology
Associate Director for Basic Research
Knight Cancer Institute
Oregon Health & Sciences University
Portland, OR

Nancy E. Davidson, M.D.
Director
University of Pittsburgh Cancer Institute
Pittsburg, PA

H. Shelton Earp III, M.D.
Director & Lineberger Professor
Professor of Medicine and Pharmacology
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Paul F. Engstrom, M.D.
Senior Vice President for Population Science
Fox Chase Cancer Center
Philadelphia, PA

Olivera J. Finn, Ph. D.
Professor & Chair, Dept. of Immunology
University of Pittsburgh School of Medicine
Pittsburg, PA

Richard I. Fisher, M.D.
Physician-in-Chief & Executive Vice President
Fox Chase Cancer Center
Senior Associate Dean
Temple University School of Medicine
Philadelphia, PA

James M. Ford, M.D.
Associate Professor of Medicine and Genetics
Stanford University School of Medicine
Stanford, CA

Susan G. Hilsenbeck, Ph.D.
Fellow of the American Statistical Association
Vice Chair, Baylor College of Medicine Institutional Review Board
Baylor College of Medicine
Houston, TX

Theodore S. Lawrence, M.D., Ph.D.
Chair, Radiation Oncology
Co-Chair, Radiation Sciences Program
University of Michigan
Comprehensive Cancer Center
Ann Arbor, MI

A. Thomas Look, M.D.
Professor, Pediatrics
Harvard Medical School
Vice Chair, Pediatric Oncology Research
Dana-Farber Cancer Institute
Harvard Cancer Center Leukemia Program
Cambridge, MA

John D. Minna, M.D.
Professor and Director, Hamon Center for Therapeutic Oncology Research
Professor, Internal Medicine & Pharmacology
Director, Center for Cancer Genetics
University of Texas Southwestern Medical Center
Dallas, TX
THE V FOUNDATION SCIENTIFIC ADVISORY BOARD IS AN EXCEPTIONAL GROUP OF PHYSICIANS AND SCIENTISTS WHO ASSURE THAT FUNDS FROM DONORS ARE INVESTED WISELY IN THE CAREERS OF THE MOST GIFTED AND MOTIVATED YOUNG INVESTIGATORS AND IN THE MOST PROMISING PROJECTS WHICH MOVE NEW DRUGS AND APPROACHES FROM THE LABORATORY TO THE CLINIC.

— DR. ROBERT BAST
### STATEMENT OF FINANCIAL POSITION
September 30, 2012

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>LIABILITIES AND NET ASSETS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td><strong>CURRENT LIABILITIES</strong></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>Accounts payable &amp; accrued expenses</td>
</tr>
<tr>
<td></td>
<td>$11,413,695</td>
</tr>
<tr>
<td>Accounts receivable, net</td>
<td>Accrued payroll &amp; related liabilities</td>
</tr>
<tr>
<td></td>
<td>55,500</td>
</tr>
<tr>
<td>Promises to give, net</td>
<td>Lease payable</td>
</tr>
<tr>
<td></td>
<td>316,918</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>Grants payable</td>
</tr>
<tr>
<td></td>
<td>56,406</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td><strong>TOTAL CURRENT LIABILITIES</strong></td>
</tr>
<tr>
<td></td>
<td>$11,842,519</td>
</tr>
<tr>
<td><strong>PROPERTY &amp; EQUIPMENT, NET</strong></td>
<td><strong>LONG-TERM LIABILITIES</strong></td>
</tr>
<tr>
<td></td>
<td>Grants payable, net</td>
</tr>
<tr>
<td></td>
<td>38,177</td>
</tr>
<tr>
<td><strong>OTHER ASSETS</strong></td>
<td><strong>TOTAL LIABILITIES</strong></td>
</tr>
<tr>
<td>Investments</td>
<td>$21,026,926</td>
</tr>
<tr>
<td>Promises to give, net</td>
<td><strong>NET ASSETS</strong></td>
</tr>
<tr>
<td></td>
<td>3,874,888</td>
</tr>
<tr>
<td><strong>TOTAL OTHER ASSETS</strong></td>
<td>Unrestricted</td>
</tr>
<tr>
<td></td>
<td>24,901,814</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>Temporarily restricted</td>
</tr>
<tr>
<td>$36,782,510</td>
<td>3,827,663</td>
</tr>
<tr>
<td></td>
<td>Permanently restricted</td>
</tr>
<tr>
<td></td>
<td>138,643</td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL NET ASSETS</strong></td>
</tr>
<tr>
<td></td>
<td>13,687,222</td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
</tr>
<tr>
<td></td>
<td>2,908,465</td>
</tr>
</tbody>
</table>

### STATEMENT OF ACTIVITIES & CHANGES IN NET ASSETS
For the Year Ended September 30, 2012

<table>
<thead>
<tr>
<th>SUPPORT AND REVENUE</th>
<th>UNRESTRICTED</th>
<th>TEMPORARILY RESTRICTED</th>
<th>PERMANENTLY RESTRICTED</th>
<th>TOTALS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and gifts</td>
<td>$9,287,602</td>
<td>$936,206</td>
<td>$2,533,706</td>
<td>$12,757,514</td>
</tr>
<tr>
<td>Special events income, net of expenses</td>
<td>3,827,663</td>
<td>-</td>
<td>-</td>
<td>3,827,663</td>
</tr>
<tr>
<td>Investment income</td>
<td>138,643</td>
<td>322,984</td>
<td>-</td>
<td>461,627</td>
</tr>
<tr>
<td>Unrealized gain on investments</td>
<td>320,457</td>
<td>813,615</td>
<td>-</td>
<td>1,134,072</td>
</tr>
<tr>
<td>Realized gain on investments</td>
<td>112,857</td>
<td>286,511</td>
<td>-</td>
<td>399,368</td>
</tr>
<tr>
<td><strong>TOTAL SUPPORT AND REVENUE</strong></td>
<td>16,595,687</td>
<td>(549,149)</td>
<td>2,533,706</td>
<td>18,580,244</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EXPENSES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td>15,537,636</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td>-</td>
</tr>
<tr>
<td>Management and general</td>
<td>724,916</td>
</tr>
<tr>
<td>Supporting Services</td>
<td></td>
</tr>
<tr>
<td>Fundraising expenses</td>
<td>769,755</td>
</tr>
<tr>
<td><strong>TOTAL SUPPORTING SERVICES</strong></td>
<td>1,494,671</td>
</tr>
<tr>
<td><strong>SUBTOTAL EXPENSES</strong></td>
<td>17,032,307</td>
</tr>
<tr>
<td>Loss from bad debts</td>
<td>-</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td>17,032,307</td>
</tr>
<tr>
<td><strong>CHANGES IN NET ASSETS</strong></td>
<td>(436,620)</td>
</tr>
<tr>
<td><strong>NET ASSETS - BEGINNING OF YEAR</strong></td>
<td>(2,770,420)</td>
</tr>
<tr>
<td><strong>NET ASSETS - END OF YEAR</strong></td>
<td>($3,207,040)</td>
</tr>
</tbody>
</table>

| **NET ASSETS - END OF YEAR**                | $3,834,726   |
| **TOTAL LIABILITY AND NET ASSETS**         | $15,756,112  |
| **TOTAL NET ASSETS**                       | $16,383,798  |
### GRANT DISTRIBUTIONS BY CANCER SITE, 1994-2012

<table>
<thead>
<tr>
<th>Grants</th>
<th>Cancer Site</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>176</td>
<td>General Cancer/Other</td>
<td>$21,393,992</td>
</tr>
<tr>
<td>66</td>
<td>Leukemia/Lymphoma</td>
<td>$17,375,000</td>
</tr>
<tr>
<td>53</td>
<td>Breast</td>
<td>$10,515,000</td>
</tr>
<tr>
<td>45</td>
<td>Pediatric</td>
<td>$13,159,000</td>
</tr>
<tr>
<td>31</td>
<td>Lung</td>
<td>$8,850,000</td>
</tr>
<tr>
<td>26</td>
<td>GI</td>
<td>$3,776,562</td>
</tr>
<tr>
<td>24</td>
<td>Prostate</td>
<td>$4,410,000</td>
</tr>
<tr>
<td>17</td>
<td>Melanoma</td>
<td>$6,250,000</td>
</tr>
<tr>
<td>13</td>
<td>Pancreatic</td>
<td>$5,050,000</td>
</tr>
<tr>
<td>10</td>
<td>Pediatric</td>
<td>$13,159,000</td>
</tr>
<tr>
<td>10</td>
<td>Brain</td>
<td>$3,050,000</td>
</tr>
<tr>
<td>8</td>
<td>Gyn./Cervical/Ovarian</td>
<td>$1,900,000</td>
</tr>
<tr>
<td>7</td>
<td>Renal</td>
<td>$2,686,500</td>
</tr>
<tr>
<td>6</td>
<td>Head and Neck</td>
<td>$1,350,000</td>
</tr>
<tr>
<td>6</td>
<td>Myeloma</td>
<td>$500,000</td>
</tr>
<tr>
<td>5</td>
<td>Ewings</td>
<td>$775,000</td>
</tr>
<tr>
<td>3</td>
<td>Colon</td>
<td>$350,000</td>
</tr>
<tr>
<td>496</td>
<td>Total</td>
<td>$101,391,054</td>
</tr>
</tbody>
</table>

### TOP 15 GRANT DISTRIBUTIONS BY STATE, 1994-2012

<table>
<thead>
<tr>
<th>State</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA</td>
<td>$20,296,312</td>
</tr>
<tr>
<td>NC</td>
<td>$11,170,954</td>
</tr>
<tr>
<td>MA</td>
<td>$10,900,000</td>
</tr>
<tr>
<td>TX</td>
<td>$7,684,697</td>
</tr>
<tr>
<td>FL</td>
<td>$7,661,860</td>
</tr>
<tr>
<td>NY</td>
<td>$6,179,861</td>
</tr>
<tr>
<td>PA</td>
<td>$5,456,709</td>
</tr>
<tr>
<td>MD</td>
<td>$4,956,200</td>
</tr>
<tr>
<td>OH</td>
<td>$3,852,017</td>
</tr>
<tr>
<td>TN</td>
<td>$3,000,000</td>
</tr>
<tr>
<td>IL</td>
<td>$2,505,750</td>
</tr>
<tr>
<td>VA</td>
<td>$2,202,650</td>
</tr>
<tr>
<td>MN</td>
<td>$1,804,322</td>
</tr>
<tr>
<td>IN</td>
<td>$1,729,175</td>
</tr>
<tr>
<td>NJ</td>
<td>$1,450,000</td>
</tr>
</tbody>
</table>